Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Grass Pollen Allergy - Overview
Grass Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Grass Pollen Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Grass Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
ASIT Biotech SA
Biomay AG
DC4U BV
HAL Allergy BV
Regeneron Pharmaceuticals Inc
Grass Pollen Allergy - Drug Profiles
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Grass Pollen Allergy - Dormant Projects
Grass Pollen Allergy - Discontinued Products
Grass Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 20, 2019: ASIT biotech discloses next steps following gp-ASIT+ phase III results
Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme
Nov 25, 2019: ASIT biotech gp-ASIT+ phase III trial in Grass Pollen Allergy did not meet the primary endpoint
Oct 17, 2019: ASIT biotech mode of action study of gp-ASIT+ for Grass Pollen Allergy published in The Jourl of Allergy and Clinical Immunology (JACI)
Sep 26, 2019: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy
Sep 05, 2019: Successful pollen season confirms Asit Biotech on track for phase III results of gp-ASIT+ in December 2019
Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial
May 02, 2019: ASIT biotech announces the achievement of new clinical and corporate development milestones
Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update
Mar 29, 2019: ASIT biotech’s scientific advisory boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+
Mar 05, 2019: ASIT biotech Reveals the Mode of Action of Its Lead Immunotherapy Product for Allergic Rhinitis, gp-ASIT+, in The Jourl of Allergy and Clinical Immunology (JACI)
Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis
Jan 16, 2019: Ongoing Restructuring of ASIT biotech Organization to Maximize the Success of gp-ASIT+ in Grass Pollen Rhinitis
Nov 19, 2018: ASIT biotech launches its confirmatory phase III clinical study with gp-ASIT+ in grass pollen rhinitis prevention following the investigator meeting hosted in Prague (Czech Republic)
Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Grass Pollen Allergy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Grass Pollen Allergy, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Grass Pollen Allergy - Pipeline by ALK-Abello AS, H2 2020
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2020
Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H2 2020
Grass Pollen Allergy - Pipeline by Biomay AG, H2 2020
Grass Pollen Allergy - Pipeline by DC4U BV, H2 2020
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2020
Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Grass Pollen Allergy - Dormant Projects, H2 2020
Grass Pollen Allergy - Discontinued Products, H2 2020